Navigation Links
Genetic predictor of breast cancer response to chemotherapy
Date:5/11/2012

Chemotherapy is a major first line defense against breast cancer. However a patient's response is often variable and unpredictable. A study published in BioMed Central's open access journal BMC Medical Genomics shows that 'gene expression signatures' for TOP2A and β-tubulin can be used to predict the outcome of chemotherapy.

The goal of personalized medicine in cancer treatment is to target therapy to the characteristics of the individual tumor. For example Herceptin treatment is of most benefit to patients whose cancer is driven by HER2 and antiestrogens benefit patients whose breast cancer is hormonally driven. Gene signatures are increasingly available for different cancer types and can be used to predict patient prognosis.

Researchers from McMaster University, in association with the Juravinski Hospital and Cancer Center, analyzed the expression of the enzyme TOP2A (DNA topoisomerase) and β-tubulin, which are the targets of commonly used chemotherapy drugs (anthracycline and taxane) in hundreds of breast tumors. Combining the results from the tumor samples analyses allowed the researchers to build gene expression 'signatures' that measure the susceptibility of tumor cells to chemotherapy.

Both of the 'signatures' were separately able to predict which patients achieved a complete response (where invasive or metastatic cancer could no longer be detected) and together the two indices together were even more accurate at predicting response to chemotherapy.

Prof John Hassell, who led this study, commented, " Our results clearly demonstrate the practicality of using gene expression to personalize chemotherapy treatment for breast cancer patients. Identifying patients who will not benefit from a specific treatment means that they can be moved to a different treatment plan, and the earlier appropriate treatment is started the more likely it is that the patients will benefit from it."


'/>"/>
Contact: Dr. Hilary Glover
hilary.glover@biomedcentral.com
44-020-319-22370
BioMed Central
Source:Eurekalert

Page: 1

Related medicine news :

1. Advanced genetic screening method may speed vaccine development
2. Genetic abnormalities in benign or malignant tissues predict relapse of prostate cancer
3. Some women may be genetically predisposed to smoking-related hot flashes
4. Genetically modified T cell therapy shown to be safe, lasting in decade-long study of HIV patients
5. Moffitt researcher awarded GE grant to develop tool to detect breast cancer metastasis genetic risks
6. Research Gets Closer to Genetic Roots of Glaucoma
7. Genetic variants, tobacco exposure and lung cancer risk
8. Study of half siblings provides genetic clues to autism
9. Certain Genetic Regions May Be Tied to Osteoporosis
10. Head, Body Lice Are Genetically Very Similar
11. 2 genetic deletions in human genome linked to the development of aggressive prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... DC (PRWEB) , ... March 30, 2017 , ... ... and organizations submitted a letter to President Trump expressing their support for an ... medical doctors, two Ph.D. scientists and one medical journalist, will hold a press ...
(Date:3/29/2017)... ... March 29, 2017 , ... In the United States alone, ... each year develop other types of metastatic brain tumors(3). Though most meningiomas are benign, ... efforts focus on finding more effective treatment options, the San Diego Gamma Knife ...
(Date:3/29/2017)... ... ... the main cause of hay fever in the United States, with an estimated 95 percent ... to July each year; with the worst time for sufferers being June and July. ... ) provide an effective defense against grass pollen; they are proven in independent studies to ...
(Date:3/29/2017)... ... March 30, 2017 , ... Sublime Naturals and its founder, Kathy Heshelow, are ... it has been used for thousands of years. , "The West has caught on, ... " Turmeric: How to Use it For Your Wellness. Overcome Inflammation, Enemy of the ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... ... three Hours at a Walgreens store in Mississippi. AngioGenesis Labs, makers of HeartBoost, ... Stores in two southeastern states. Ingredients in HeartBoost, an over the counter heart ...
Breaking Medicine News(10 mins):
(Date:3/30/2017)... PHILADELPHIA , March 30, 2017  Lannett Company, ... the company voluntarily made a $25 million payment against ... $25 million payment, combined with the $75 million payment ... us approximately $5.5 million in annualized cash interest expense, ... executive officer of Lannett.  "Our business is solid and ...
(Date:3/30/2017)... Research and Markets has announced the ... & Forecast, By Type (Hemodialysis, Peritoneal Dialysis), By Product (Device, ... 2014 To 2025" report to their offering. ... The global ... 108.5 billion by 2025. Home-based dialysis ...
(Date:3/29/2017)... 29, 2017  Bodycad announced today that it ... 510(k) clearance for its Bodycad Unicompartmental Knee System, ... orthopaedic restoration. Bodycad is the first Canadian company ... implant system. Bodycad,s revolutionary Unicompartmental ... of the patient,s unique anatomical features and kinematics. ...
Breaking Medicine Technology: